Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

CT-868

Stage Phase 2Stale

Sponsor Carmot Therapeutics, Inc

Route injection

Sources

registry, as of 2026-10-28Stale

https://clinicaltrials.gov/study/NCT06062069

A Study of CT-868 in Type 1 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE2. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 111. Conditions Overweight; Obese; Type 1 Diabetes Mellitus. This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabet Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20% Weight Loss at Week 16 Arm 1: All Placebo 2.0 Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20% Weight Loss at Week 16 Arm 2: CT-868 Titrated to 1.8 mg 6.0 Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20% Weight Loss at Week 16 Arm 3: CT-868 Titrated to 4.1 mg 15.0 Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20%

ClinicalTrials.gov NCT06062069 protocol and results modules

registry, as of 2026-02-05Stale

https://clinicaltrials.gov/study/NCT05110846

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE2. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 103. Conditions Obesity; Overweight; Type 2 Diabetes Mellitus. A study to assess the effect of CT-868 in lowering glycated hemoglobin A1c (HbA1c) in overweight and obese participants with inadequately controlled Type 2 diabetes mellitus (T2DM).

ClinicalTrials.gov NCT05110846 protocol and results modules

registry, as of 2024-12-27Stale

https://clinicaltrials.gov/study/NCT05794581

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes. Overall status COMPLETED. Phases PHASE1. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 32. Conditions Type 1 Diabetes. This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

ClinicalTrials.gov NCT05794581 protocol and results modules

registry, as of 2025-03-28Stale

https://clinicaltrials.gov/study/NCT04973111

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose. Overall status COMPLETED. Phases PHASE1. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 32. Conditions Diabetes. A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.

ClinicalTrials.gov NCT04973111 protocol and results modules

Studies

A Study of CT-868 in Type 1 Diabetes Mellitus

Registry NCT06062069

Phase Phase 2

Status Completed

Enrollment 111

Start 2023-11-27

Primary completion 2025-07-07

Study completion 2025-07-07

Catalyst Primary completion. 2025-07-07. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CT-868 Low Dose

Regimen once daily

Weeks 16

Comparator placebo

Population Overweight; Obese; Type 1 Diabetes Mellitus

CT-868 Medium Dose

Regimen once daily

Weeks 16

Comparator placebo

Population Overweight; Obese; Type 1 Diabetes Mellitus

CT-868 High Dose

Regimen once daily

Weeks 16

Comparator placebo

Population Overweight; Obese; Type 1 Diabetes Mellitus

CT-868 Placebo

Regimen once daily

Weeks 16

Population Overweight; Obese; Type 1 Diabetes Mellitus

participants with at least 5 percent body weight loss, 2 %, week 16Stale

deaths

participants with diarrhoea, 2 participantsStale

participants with nausea, 2 participantsStale

participants with vomiting, 0 participantsStale

Arm 2: CT-868 Titrated to 1.8 mg

Dose 1.8 mg

Regimen once daily

Weeks 16

Population Overweight; Obese; Type 1 Diabetes Mellitus

participants with at least 5 percent body weight loss, 6 %, week 16Stale

deaths

participants with diarrhoea, 6 participantsStale

participants with nausea, 13 participantsStale

participants with vomiting, 4 participantsStale

Arm 3: CT-868 Titrated to 4.1 mg

Dose 4.1 mg

Regimen once daily

Weeks 16

Population Overweight; Obese; Type 1 Diabetes Mellitus

participants with at least 5 percent body weight loss, 15 %, week 16Stale

deaths

participants with diarrhoea, 6 participantsStale

participants with nausea, 17 participantsStale

participants with vomiting, 8 participantsStale

Arm 4: CT-868 Titrated to 6.6 mg

Dose 6.6 mg

Regimen once daily

Weeks 16

Population Overweight; Obese; Type 1 Diabetes Mellitus

participants with at least 5 percent body weight loss, 15 %, week 16Stale

deaths

participants with diarrhoea, 6 participantsStale

participants with nausea, 9 participantsStale

participants with vomiting, 8 participantsStale

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Registry NCT05110846

Phase Phase 2

Status Completed

Enrollment 103

Start 2022-02-22

Primary completion 2023-02-28

Study completion 2023-02-28

Placebo

Regimen once daily

Weeks 26

Population Obesity; Overweight; Type 2 Diabetes Mellitus

CT-868 1.75 mg

Dose 1.75 mg

Regimen once daily

Weeks 26

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes Mellitus

CT-868 4.0 mg

Dose 4.0 mg

Regimen once daily

Weeks 26

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes Mellitus

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

Registry NCT05794581

Phase Phase 1

Status Completed

Enrollment 32

Start 2023-03-21

Primary completion 2024-03-06

Study completion 2024-04-06

CT-868

Comparator placebo

Population Type 1 Diabetes

Placebo

Population Type 1 Diabetes

Victoza

Comparator placebo

Population Type 1 Diabetes

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

Registry NCT04973111

Phase Phase 1

Status Completed

Enrollment 32

Start 2021-07-16

Primary completion 2022-04-22

Study completion 2022-04-22

CT-868

Comparator placebo

Population Diabetes

Placebo

Population Diabetes

Active Comparator

Comparator placebo

Population Diabetes